No Data
No Data
Sichuan Huiyu Pharmaceutical Gets Nod to Market Osteoporosis Drug in Netherlands
Huiyu Pharmaceutical (688553.SH): Zolendronic acid injection received Dutch market approval.
On August 12th, Globio reports that Huayu Pharmaceutical (688553.SH) announced that its wholly-owned subsidiary, SeacrossPharma (Europe) Ltd., recently received approval from the Dutch Health Products Regulatory Agency to market its product, Zoledronic acid injection. Zoledronic acid injection is mainly used for the treatment of osteoporosis in postmenopausal women and adult men, osteoporosis induced by long-term glucocorticoid treatment in postmenopausal women and adult men, and Paget's disease of bone in adults.
Huiyu Pharmaceutical (688553.SH): Azacitidine for injection and bendamustine hydrochloride for injection obtained marketing approval in Uzbekistan
On August 7th, Gelunhui reported that Seacross Pharmaceuticals Ltd., a wholly-owned subsidiary of Huiyu Pharmaceutical (688553.SH), recently received approval and issuance of the license for the injection of Azacitidine and injection of Benidipine Hydrochloride for the company's product from the Uzbekistan Pharmaceutical Authority. Azacitidine injection is a cytidine nucleoside analogue that exerts an antitumor effect by causing DNA demethylation and direct cytotoxic effects on aberrant hematopoietic cells in the bone marrow. The injection of benidipine hydrochloride is used for chronic lymphocytic leukemia in patients who are not suitable for fludarabine-based combined chemotherapy.
Huiyu Pharmaceutical Gets Nod to Market Two Cancer Drugs
Huayu Pharmaceutical (688553.SH): Injection of Calcium Levofolinate and Methotrexate Injection received the pharmaceutical registration certificate.
On August 6th, Gelonghui reported that Huiyu Pharmaceutical (688553.SH) announced that the company received the "Drug Registration Certificate" issued and approved by the National Medical Products Administration. Calcium folinate enhances the efficacy and toxic effects of fluorouracil (such as 5-fluorouracil) in tumor treatment. 5-Fluorouracil is metabolized to 5-fluoro-2'-deoxyuridine-5'-phosphate (FdUMP), which combines and inhibits thymidylate synthase (an enzyme that is very important in DNA repair and replication). In the body, calcium folinate can easily be converted to another reduced folate, 5,10-methylenetetrahydrofolate, which can stabilize deamination.
Huiyu Pharmaceutical Unit's Two Drugs Gets Nod to Be Marketed in Costa Rica, Ireland
No Data